

GRADUATE CERTIFICATE IN PHARMACEUTICAL REGULATION

GMS5003: Fundamentals of Health Products Regulation

15 – 19 September 2025

Venue: Training Room 5C (Level 5),

Duke-NUS Medical School, 8 College Rd, Singapore 169857

Please note that the venue will be relocated to Room 3D (Level 3, Duke-NUS Medical School) only for 16 September 2025 (Tuesday).

WORKSHOP PROGRAMME

Learning outcomes

- Explain the foundational basis of regulatory management and decision-making for health products
- Explain the essential principles in managing pharmaceuticals across their life cycles
- Describe the regulatory requirements for the different product development phases
- Relate to the real-life settings in regulatory decision-making through hands-on practical sessions
- Recognize the major regulatory organisations steering the innovation of regulatory processes and focus

Graduate Certificate in Pharmaceutical Regulation

GMS5003: Fundamentals of Health Products Regulation

15 – 19 September 2025

Day 1 – 15 September 2025, Mon

Topic		Speaker/ Organisation
Session 1: Overview of Pharmaceutical Development, Regulations & Commercialisation Strategies		
8.30 am	Introduction to Pharmaceutical Regulations- A Regulator's Perspective <ul style="list-style-type: none"> Purposes & Scope of regulation Role of regulation in healthcare systems Evolution of regulatory frameworks Regulatory convergence Regulatory cooperation/ reliance HTA and patient perspectives 	Prof John Skerritt Former Deputy Secretary Health Products Regulation, Australian Department of Health and Aged Care Enterprise Professor in Health Research Impact, University of Melbourne, Australia Adjunct Professor, Faculty of Medicine and Health, University of Sydney, Australia
9.15 am	Welcome Graduate Certificate Students	Dr Rathi Saravanan Lead Education Associate Lead, Graduate Certificate Programme Centre of Regulatory Excellence (CoRE) Duke-NUS Medical School
9.45 am	Workshop Briefing	Dr Uttara Soumyanarayanan Senior Education Associate CoRE, Duke-NUS Medical School
10.00 am	Brightspace and Assessment Familiarization	Mr. Osman Bin Mohamad Senior Education Associate CoRE, Duke-NUS Medical School
10.40 am	Photo-taking with Participants & Faculty	CoRE Education Team
10.45 am	Refreshment Break	
11.00 am	Regulatory Processes Across Pharmaceutical Products Lifecycle – Industry Perspective <ul style="list-style-type: none"> Role of industry in supporting product life cycle management Different regulatory pathways across market Country-specific requirements Novel health products Optimising engagement with regulators Challenges for industry 	TBD
12.30 pm	Lunch	
1.30 pm	Regulatory landscape in ASEAN region <ul style="list-style-type: none"> Broad overview of ASEAN NRAs and their scope of regulation: focus on HSA, NPRA, BPOM Initiatives like ASEAN PPWG, Joint Assessment, Pharmaceutical Regulatory Framework (APRF) 	Ms Sandy Chan Associate Director, Asia Pacific Regulatory Policy & Intelligence Lead, The Janssen Pharmaceutical Companies of Johnson & Johnson
2.15 pm	Role of stakeholder interactions for effective regulatory decision making <ul style="list-style-type: none"> Pre-consultations in guiding development Importance of stakeholder interactions in ensuring SEQ of pharmaceutical products Role of regulatory professionals 	Mr Thean Soo (TS) LO Independent Consultant TS Consulting
3.00 pm	Refreshment Break	
3.15 pm	Commercialization strategies for pharmaceutical products <ul style="list-style-type: none"> Significance of TPP in product development and market entry Regulatory activities in the context of 	Mr. Andy Li Senior Executive NUS Enterprise National University of Singapore (NUS)

- commercialization and ensuring regulatory compliance in tech transfer
- Assessing the commercial potential of innovations and inventions
 - Case examples

Session 2: Ensuring Quality, Safety and Efficacy of Pharmaceutical Products

4.15 pm	Overview of Chemistry, Manufacturing and Controls	Dr Rathi Saravanan CoRE, Duke-NUS Medical School
	<ul style="list-style-type: none"> • Concept of pharmaceutical quality (PQ/CMC) • Importance and impact of pharmaceutical quality on patient safety • Pharmaceutical quality initiatives • Key regulatory guidelines and requirements • General practices in the industry providing quality assurance 	

5.15 pm	Debrief and Announcements	CoRE Education Team
----------------	----------------------------------	----------------------------

5.30pm	End of Day 1
---------------	---------------------

Day 2 – 16 September 2025, Tue

Please note that the venue will be relocated to Room 3D (Level 3, Duke-NUS Medical School) only for Tuesday, 16 September 2025.

Topic		Speaker/ Organisation
8.30 am	Good Manufacturing Practices (GMP): Main Concepts <ul style="list-style-type: none"> Failures in GMP GMP history Basic GMP requirements including definition and quality management 	Ms Smitha Kenchath Consultant Seer Pharma (Singapore) Pte Ltd
9.30 am	Networking Session	Mr. Osman Bin Mohamad CoRE, Duke-NUS Medical School
10.00 am	Break	
10.45 am	Overview of Nonclinical requirements for pharmaceuticals <ul style="list-style-type: none"> Types of Nonclinical studies Data for FIH studies 	TBD
11.45 am	Overview of Good Clinical Practice (GCP) requirements and clinical trial application (CTA) for pharmaceuticals <ul style="list-style-type: none"> Principles of GCP Key GCP guidelines (WHO/ICH/HSA) CTA vs CTN 	Dr Yeo Jing Ping Vice President, Clinical Operations & Head, Asia Pacific Precision for Medicine
12.30 pm	Lunch	
1.30 pm	Overview of pharmaceuticals clinical development <ul style="list-style-type: none"> Phases of Clinical Trials Design of CT: inclusion exclusion criteria, endpoints 	Dr Yeo Jing Ping Precision for Medicine
2.30 pm	Practicum I Clinical development of pharmaceuticals	Dr Yeo Jing Ping Precision for Medicine
3.00 pm	Refreshment Break	
3.15 pm	Practicum I Continued	
5.15 pm	Debrief and Announcements	CoRE Education Team
5.30 pm	End of Day 2	

Day 3 – 17 September 2025, Wed

	Topic	Speaker/ Organisation
8.30 am	Individual and Group assessment I	
Session 4: Regulatory Processes for Pharmaceutical Products		
9.30 am	Market Authorisation Application <ul style="list-style-type: none"> Requirements for MAA submission and review in select countries ICH CTD submission requirements 	Asst/Prof James Leong Head Health Products & Regulatory Science CoRE, Duke-NUS Medical School
10.30 am	Refreshment Break	
10.45 am	Regulatory requirements for regulatory decision making: Benefit-risk analysis <ul style="list-style-type: none"> Benefit-risk assessment for regulatory decision making 	Asst/Prof James Leong CoRE, Duke-NUS Medical School
12.00 pm	Lunch	
1.00 pm	Practicum II Benefit-Risk Assessment of Pharmaceutical Products	Expert Faculty: Asst/Prof James Leong
3.30 pm	Refreshment Break	
3.45 pm	Facilitated Regulatory Pathways with Case Examples <ul style="list-style-type: none"> Expedited pathways, accelerated Designations: Orphan, breakthrough Regulatory Cooperation Regulatory Agility Case Examples 	Prof Lawrence Liberty USC Mann School of Pharmacy and Pharmaceutical Sciences Director, The DK Kim International Center for Regulatory Science Associate Professor, Department of Regulatory and Quality Sciences
4.30 pm	Good Registration Management (GRM) <ul style="list-style-type: none"> WHO GRevP (Good Review Practices) GSubP (Good Submission Practices) 	Mr Thean Soo (TS) LO TS Consulting
5.20 pm	Debrief and Announcements	CoRE Education Team
5.30pm	End of Day 3	

Day 4 – 18 September 2025, Thurs

Topic		Speaker/ Organisation
Session 5: Post-approval processes and product lifecycle management		
8.30 am	Managing post-approval quality changes <ul style="list-style-type: none"> • Risk based approach to post-approval changes • Reliance practices in post-approval CMC changes 	Ms Jacinta Watt, Director, Pharmaceutical Chemistry Variations Section, Therapeutics Goods Administration Australia
9.30 am	GMP compliance, Audit and Inspections <ul style="list-style-type: none"> • Types of GMP inspections • Common GMP Inspection Findings • GMP Audit Deficiencies 	Ms Smitha Kenchath Seer Pharma (Singapore) Pte Ltd
10.30 am	Refreshment Break	
10.45 am	Overview of Pharmacovigilance for Pharmaceutical Products <ul style="list-style-type: none"> • Introduction to pharmacovigilance • Appreciation of the pharmacovigilance framework • Risk management plans and post-marketing activities 	Dr Han Phey Yen Regulatory Consultant Vigilance & Compliance Branch Health Sciences Authority, Singapore
12.00 pm	Lunch	
1.00 pm	Case Discussion I <ul style="list-style-type: none"> • Risk management plans for pharmaceutical products 	Expert Faculty: Dr Han Phey Yen
2:45 pm	Refreshment Break	
3.00 pm	Total Product Lifecycle (TPLC) management <ul style="list-style-type: none"> • Potential issues during pre-market activities • Potential issues during post-market activities • Quality deviations & regulatory actions • Assessing clinical impact 	Asst/Prof James Leong CoRE, Duke-NUS Medical School
4.00 pm	Case Discussion II <ul style="list-style-type: none"> • Product deviations & levels of recall 	Expert Faculty: Asst/Prof James Leong
5.15 pm	Debrief and Announcements	
5.30pm	End of Day 4	

Day 5 – 19 September 2025, Fri

	Topic	Speaker/ Organisation
9.00 am	End-of-Module (EOM) Assessment	CoRE Education Team
10.00 am	Refreshment Break	
10.15 am	Review of EOM Questions	CoRE Education Team
Session 6: Trends in Health Products Development and Regulations		
11.00 am	Introduction to Precision Health and Medicine <ul style="list-style-type: none"> Significance of biomarkers Strategies integrating drug & diagnostic development Challenges in the diagnostic development process 	Ms Valerie Mbella Director Global Regulatory Affairs Diagnostics, Johnson & Johnson Innovative Medicine
11.45 am	Introduction to Health Technology Assessment <ul style="list-style-type: none"> HTA principles & process Technology evaluation & decision-making Examples 	Mr Mohamed Ismail ABDUL AZIZ Agency for Care Effectiveness
12.30 pm	Lunch	
1.30 pm	Introduction to Healthcare Services Regulation <ul style="list-style-type: none"> Trending areas in healthcare landscape Service models and technologies in gene therapies AI in healthcare 	Asst. Prof. Kavitha Palaniappan Assistant Professor, Lead, Healthcare Services Regulation Group (HRG) CoRE, Duke-NUS Medical School
2.15 pm	Gallery Walk: Target Product Profiling <ul style="list-style-type: none"> Development of TPP for different therapeutic areas Peer Evaluation 	Mr. Andy Li NUS Enterprise
3.45 pm	Break	
4.00 pm	Reflection and Peer Sharing	Dr. Rathi Saravanan CoRE
5.00 pm	Graduate Certificate Workshop Conclusion	Prof Silke Vogel Deputy Director, CoRE Senior Associate Dean Graduate Studies Duke-NUS Medical School
5.30 pm	End of Workshop	